因塞特 INCY 深 沪
已收盘 12-12 16:00:00 美东时间
95.41
-0.690
-0.72%
华盛通- 最 高96.00
- 今 开95.76
- 成交量 226.09万股
- 最 低 93.54
- 昨 收 96.10
- 总市值 186.05亿
- 52周最高 109.275
- 市盈率 静 615.95
- 换手率 1.16%
- 52周最低 53.56
- 委 比 -24.20%
- 总股本 1.95亿
- 历史最高 153.15
- 量 比 0.91
- 振 幅 2.56%
- 历史最低 11.76
- 每 手 1
- 风险率 13.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Incyte Board Member Hervé Hoppenot Retires
Incyte ( ($INCY) ) has provided an announcement. On December 10, 2025, Hervé Ho...
12-13 00:57
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
Syndax Pharmaceuticals' Revuforj® (revumenib), a first-in-class menin inhibitor, was awarded "Best New Drug" at the 2025 Scrip Awards, recognizing its groundbreaking science and therapeutic advances in treating relapsed or refractory acute leukemias with specific genetic mutations. Revuforj, approved for two patient populations in 2024 and 2025, received the award alongside its recent expanded approval for acute myeloid leukemia (AML) with NPM1 m...
12-12 12:00
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Mizuho Upgrades Incyte to Outperform, Raises Price Target to $121
Mizuho analyst Salim Syed upgrades Incyte (NASDAQ:INCY) from Neutral to Outperform and raises the price target from $90 to $121.
12-08 21:47
FDA fast-tracks Incyte drug for rare blood cancer
Incyte (INCY) on Sunday said the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to INCA033989, an experimental antibody designed to treat patients with a specific genet...
12-07 23:31
Trevi Therapeutics appoints new CFO
Trevi Therapeutics (TRVI) named David Hastings as its next chief financial officer, effective January 6, 2026. Hastings prior roles include CFO positions at Arbutus, Unilife, and Incyte. Hastings curr...
12-04 20:43
Trevi Therapeutics Appoints Veteran Finance Leader David Hastings as New CFO Starting January 2026
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with
12-04 20:33
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Barclays Maintains Overweight on Incyte, Raises Price Target to $115
Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $101 to $115.
11-24 22:29
损失超2000亿美元，五年内即将“到期”的重磅药物
（来源：写意宣发） 11月28日-30日泰州医博会期间，同写意将组织30+场交流对接活动，邀请300+展商前来展览展示，欢迎报名演讲，参会。 “专利悬崖”浪潮...
11-17 17:24
